Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.900
+0.020 (1.06%)
Jun 12, 2026, 4:00 PM EDT - Market closed

Allogene Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
6563144525419092,128
Market Cap Growth
163.00%-30.47%-16.50%-40.41%-57.30%-39.98%
Enterprise Value
469.96139.13242.78180.99486.321,741
Last Close Price
1.901.372.133.216.2914.92
PS Ratio
--20545.805698.335823.8318.65
PB Ratio
1.671.071.071.061.362.30
P/TBV Ratio
1.551.030.980.981.352.19
EV/Sales Ratio
--11035.401905.163117.4315.26
Debt / Equity Ratio
0.260.260.200.170.140.08
Net Debt / Equity Ratio
-0.70-0.60-0.50-0.70-0.63-0.42
Net Debt / EBITDA Ratio
1.090.890.811.151.312.28
Net Debt / FCF Ratio
1.771.171.041.511.871.88
Asset Turnover
-00.000.000.000.10
Quick Ratio
9.427.708.2312.109.639.55
Current Ratio
9.657.938.5412.389.849.84
Return on Equity (ROE)
-13.58%-53.42%-55.13%-55.51%-42.76%-18.16%
Return on Assets (ROA)
-46.86%-43.40%-45.94%-44.76%-35.84%-15.82%
Return on Invested Capital (ROIC)
-135.47%-103.75%-127.57%-137.54%-76.91%-35.99%
Return on Capital Employed (ROCE)
-50.66%-46.69%-48.83%-47.72%-37.90%-16.87%
Buyback Yield / Dilution
-9.93%-13.25%-24.14%-9.63%-5.39%-12.84%
Total Shareholder Return
-9.93%-13.25%-24.14%-9.63%-5.39%-12.84%
SEC Filings: 10-K · 10-Q